UAE Trends and Developments Contributed by: Winsome Cheung and Haykel Hajjaji, Covington & Burling LLP
Regulatory Modernisation and Market Dynamics Shaping the UAE’s Life Sciences Sector Introduction The United Arab Emirates is undergoing a sustained transformation of its life sciences sector. Over recent years, and with particular acceleration since 2023, the federal government has implemented extensive regulatory reforms, expanded clinical research capac- ity, and introduced industrial and innovation poli- cies aimed at positioning the UAE as a regional hub for pharmaceuticals, biotechnology and advanced healthcare solutions. These developments form part of a broader national agenda focused on econom- ic diversification, knowledge‑based industries and long‑term healthcare resilience. Life sciences has emerged as a priority sector within this agenda. Policy initiatives increasingly emphasise local manufacturing, research and development, and the adoption of advanced technologies across the healthcare ecosystem. As a result, the UAE market is now characterised by heightened regulatory sophis- tication, clearer institutional structures, and closer alignment with international regulatory standards. At the same time, the pace and breadth of reform require careful monitoring. New federal legislation continues to be supplemented by executive regula- tions and regulatory guidance, and market partici- pants must navigate the interaction between feder- al and Emirate‑level rules, as well as the interfaces between different health authorities. This article exam- ines the principal trends shaping the UAE life sciences sector and highlights their practical implications for companies operating in, or considering entry into, the market. Market and deal trends In parallel with regulatory reform, the UAE has expe- rienced increased activity in healthcare and life sci- ences transactions across public markets, strategic M&A, venture investment, and licensing. The market continues to be shaped by government‑affiliated play- ers, healthcare platforms, and a growing pipeline of digital health and data‑driven healthcare companies. UAE public markets are becoming more significant as exit and funding routes for major healthcare platforms.
Notably, PureHealth listed on the Abu Dhabi Securities Exchange (ADX) in December 2023. The UAE remains one of the Middle East’s leading M&A markets. Healthcare M&A is driven by platform consolidation, portfolio optimisation, and the acqui- sition of technology‑enabled service capabilities. Venture capital plays an increasingly important role, especially in healthtech and data‑enabled healthcare models. Licensing transactions are also becoming more prom- inent. Most licensing involving UAE‑based companies takes the form of inbound licensing of products, tech- nologies, or know‑how, reflecting a national focus on building domestic capabilities and accelerating access to innovative healthcare solutions. These licences are often granted for the entire GCC/MENA region, con- sistent with the UAE’s role as a regional commercial hub. Recent developments also suggest diversifi- cation beyond traditional pharmaceutical licensing toward diagnostics, digital health, data analytics, and platform‑based healthcare solutions, frequently imple- mented through large, government‑affiliated health- care platforms. Regulatory consolidation and modernisation A defining recent development is the consolidation and modernisation of the regulatory framework gov- erning medical products and pharmaceutical activi- ties. Federal Decree‑Law No 38 of 2024, effective January 2025, represents a comprehensive overhaul of the previous regime and significantly expands the scope of regulated products and entities. The law explicitly covers pharmaceuticals, biopharma- ceuticals, medical devices, food supplements, cos- metics, advanced therapy products, clinical research entities, and biobanks. This broader scope reflects the convergence of healthcare technologies and the need for a unified framework capable of regulating both tra- ditional products and emerging therapies. The legislation also formalises the role of the Emirates Drug Establishment as the central federal authority responsible for marketing authorisations, pharma- covigilance, pricing oversight, and national product tracking systems. This restructuring aims to reduce
380 CHAMBERS.COM
Powered by FlippingBook